Providing next-generation regenerative medicine.
Medical advances have led to a welcome increase in life expectancy. However, this has led to a rise in age-related diseases and healthcare costs. In addition to the ageing society, increasingly active younger demographics are also prone to trauma, injury or disease, all resulting in tissue deterioration for which there are limited answers.
Renovos, a regenerative medicine company, is pioneering a nanoclay gel technology platform, Renovite®, for medical applications to address the unmet need for long term tissue regeneration, offering safer, more economic clinical solutions for health systems, and better outcomes for patients.
What’s the innovation?
Renovos is transforming regenerative medicine and orthopaedics through pioneering use of nanoclay gels from world-class stem cell research. Renovite® nanoclay gels stimulate stem cells and localise therapeutics, to make a step change improvement in their efficacy and safety. Renovite® gel formulations are injectable and can deliver and RETAIN therapeutic agents within the target site of repair, “taming” them. This allows for 100x dose reduction, lower COGS and improved safety of potent biologics. Renovite® itself is bioactive and attracts patient’s own stem cells into the area to invade the material and break it down, in time completely replacing it with regenerated tissue.
Renovos’ mission is to unlock the full potential of regenerative medicine and help clinicians deliver safe and more efficacious treatments for tissue repair, in the first instance addressing a $5.7bn orthobiologics market.
What are you looking to get from #VFS21?
At this years #VFS21 we are looking to meet with investors, other innovators and potential collaborators.